Predicting Time to Readmission in Patients With Recent Histories of Recurrent Psychiatric Hospitalization A Matched-Control Survival Analysis

被引:43
|
作者
Schmutte, Timothy [2 ]
Dunn, Christine L. [2 ]
Sledge, William H. [1 ,2 ]
机构
[1] Yale New Haven Psychiat Hosp, New Haven, CT 06519 USA
[2] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
关键词
Severe mental illness; inpatient utilization; hospitalization; SEVERE MENTAL-ILLNESS; NURSING-HOMES; REHOSPITALIZATION; SCHIZOPHRENIA; CARE;
D O I
10.1097/NMD.0b013e3181fe726b
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The most robust predictor of future psychiatric hospitalization is the number of previous admissions. About half of psychiatric inpatients with histories of repeated hospitalizations are readmitted within 12 months. This study sought to determine which patient characteristics predicted time-to-readmission within 12 months after controlling for the number of previous hospitalizations in 75 adults with recent histories of recurrent admissions and 75 matched controls. Results revealed multiple clinical and demographic between-group differences at index hospitalization. However, the only predictors of shorter time-to-readmission in multivariate Cox proportional hazards were unemployment (hazards ratio = 9.26) and residential living status (hazards ratio = 2.05) after controlling for prior hospitalizations (hazard ratio = 1.24). Unemployment and residential living status were not proxies of psychosis or moderated by illness severity or comorbid substance use. Results suggest that early psychiatric readmission may be more influenced by residential and employment status than by severe mental illness.
引用
下载
收藏
页码:860 / 863
页数:4
相关论文
共 50 条
  • [31] Texture Analysis of the Apparent Diffusion Coefficient Focused on Contrast-Enhancing Lesions in Predicting Survival for Bevacizumab-Treated Patients with Recurrent Glioblastoma
    Lopez-Rueda, Antonio
    Puig, Josep
    Thio-Henestrosa, Santiago
    Moreno-Negrete, Javier Luis
    Zwanzger, Christian
    Pujol, Teresa
    Aldecoa, Iban
    Pineda, Estela
    Valduvieco, Izaskun
    Gonzalez, Jose Juan
    Oleaga, Laura
    CANCERS, 2023, 15 (11)
  • [32] Patients with Type 2 Diabetes Benefit from Primary Care-Based Disease Management: A Propensity Score Matched Survival Time Analysis
    Drabik, Anna
    Buescher, Guido
    Thomas, Karsten
    Graf, Christian
    Mueller, Dirk
    Stock, Stephanie
    POPULATION HEALTH MANAGEMENT, 2012, 15 (04) : 241 - 247
  • [33] MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.
    Sampson, John H.
    Achrol, Achal
    Aghi, Manish K.
    Bankiewicz, Krystof
    Bexon, Martin
    Brem, Steven
    Brenner, Andrew Jacob
    Chandhasin, Chandtip
    Chowdhary, Sajeel A.
    Coello, Melissa
    Das, Sunit
    Han, Seunggu Jude
    Kesari, Santosh
    Merchant, Fahar
    Merchant, Nina
    Randazzo, Dina
    Vogelbaum, Michael A.
    Vrionis, Frank
    Zabek, Miroslaw
    Butowski, Nicholas A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] SURVIVAL ANALYSIS OF 496 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WITH UP TO 40 YEARS FOLLOW-UP SHOWS IMPROVED SURVIVAL IN PATIENTS DIAGNOSED IN MORE RECENT TIME-PERIODS
    Luo, Weike
    Farinha, Filipa
    Isenberg, David A.
    Rahman, Anisur
    RHEUMATOLOGY, 2022, 61 : I5 - I5
  • [35] Analysis of microRNA expression profiles reveals a 5-microRNA prognostic signature for predicting overall survival time in patients with gastric adenocarcinoma
    Zhao, Ruihong
    Zhao, Lei
    Xu, Xu
    Xu, Hong
    ONCOLOGY REPORTS, 2019, 41 (05) : 2775 - 2789
  • [36] T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar responsiveness to chemotherapy: A matched-control analysis on 50 patients.
    Bouabdallah, R
    Mounier, N
    Guettier, C
    Molina, T
    Thieblemont, C
    Sonet, A
    Delmer, A
    Gaulard, P
    Gisselbrecht, C
    Xerri, L
    BLOOD, 2002, 100 (11) : 160A - 160A
  • [37] Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)
    Thanawat Rattanathammethee
    Lalita Norasetthada
    Udomsak Bunworasate
    Kitsada Wudhikarn
    Jakrawadee Julamanee
    Panarat Noiperm
    Theerin Lanamtieng
    Pisa Phiphitaporn
    Manassamon Navinpipat
    Piyapong Kanya
    Dusit Jit-ueakul
    Somchai Wongkhantee
    Thanongsak Suwannathen
    Juthatip Chaloemwong
    Peerapon Wong
    Nisa Makruasi
    Archrob Khuhapinant
    Kannadit Prayongratana
    Pimjai Niparuck
    Nonglak Kanitsap
    Tawatchai Suwanban
    Tanin Intragumtornchai
    Annals of Hematology, 2023, 102 : 1887 - 1895
  • [38] Impact of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma (the MEMOIR study): A propensity score-matched analysis
    Qian, D. C.
    Kleber, T.
    Brammer, B.
    Xu, K. M.
    Switchenko, J. M.
    Janopaul-Naylor, J. R.
    Zhong, J.
    Yushak, M. L.
    Harvey, R. D.
    Paulos, C. M.
    Lawson, D. H.
    Khan, M. K.
    Kudchadkar, R. R.
    Buchwald, Z. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S12 - S12
  • [39] The potential of the transformer-based survival analysis model, SurvTrace, for predicting recurrent cardiovascular events and stratifying high-risk patients with ischemic heart disease
    Shinohara, Hiroki
    Kodera, Satoshi
    Nagae, Yugo
    Hiruma, Takashi
    Kobayashi, Atsushi
    Sato, Masataka
    Sawano, Shinnosuke
    Kamon, Tatsuya
    Narita, Koichi
    Hirose, Kazutoshi
    Kiriyama, Hiroyuki
    Saito, Akihito
    Miura, Mizuki
    Minatsuki, Shun
    Kikuchi, Hironobu
    Takeda, Norifumi
    Akazawa, Hiroshi
    Morita, Hiroyuki
    Komuro, Issei
    PLOS ONE, 2024, 19 (06):
  • [40] Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)
    Rattanathammethee, Thanawat
    Norasetthada, Lalita
    Bunworasate, Udomsak
    Wudhikarn, Kitsada
    Julamanee, Jakrawadee
    Noiperm, Panarat
    Lanamtieng, Theerin
    Phiphitaporn, Pisa
    Navinpipat, Manassamon
    Kanya, Piyapong
    Jit-ueakul, Dusit
    Wongkhantee, Somchai
    Suwannathen, Thanongsak
    Chaloemwong, Juthatip
    Wong, Peerapon
    Makruasi, Nisa
    Khuhapinant, Archrob
    Prayongratana, Kannadit
    Niparuck, Pimjai
    Kanitsap, Nonglak
    Suwanban, Tawatchai
    Intragumtornchai, Tanin
    ANNALS OF HEMATOLOGY, 2023, 102 (07) : 1887 - 1895